Cargando…
Mass spectrometry in drug metabolism and disposition : basic principles and applications /
"This book examines the background, industrial context, process, analytical methodology, and technology of metabolite identification. It emphasizes the applications of metabolite identification in drug research. While primarily a textbook, the book also functions as a comprehensive reference to...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken, N.J. :
Wiley,
©2011.
|
| Colección: | Wiley series on pharmaceutical science and biotechnology.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn716211010 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 110428s2011 nyu ob 001 0 eng d | ||
| 010 | |z 2010028341 | ||
| 040 | |a UIU |b eng |e pn |c UIU |d DG1 |d E7B |d CDX |d YDXCP |d OCLCQ |d EBLCP |d IDEBK |d OCLCQ |d OCLCO |d UIU |d N$T |d OCLCQ |d UKDOC |d OCLCQ |d NLGGC |d OCLCQ |d COO |d OCLCQ |d DEBBG |d LOA |d OCLCQ |d OCLCO |d OCLCA |d COCUF |d DG1 |d CHVBK |d OCLCO |d OCLCO |d OCLCQ |d MOR |d LIP |d OCLCO |d PIFAG |d MERER |d OCLCO |d ZCU |d OCLCQ |d MERUC |d OCLCQ |d GWDNB |d OCLCO |d OCLCA |d U3W |d OCLCA |d OCLCQ |d OCLCF |d OCLCO |d STF |d WRM |d OCLCO |d NRAMU |d ICG |d INT |d VT2 |d AU@ |d OCLCO |d OCLCQ |d CUY |d WYU |d OCLCO |d OCLCA |d YOU |d OCLCA |d UWO |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d UX1 |d OL$ |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d UKCRE |d OCLCA |d OCLCO |d UKAHL |d OCLCO |d OCLCQ |d OCL |d INARC |d OCLCO |d OCLCL |d OCLCQ |d OCLCA |d OCLCL | ||
| 066 | |c (S | ||
| 016 | 7 | |a 1066428301 |2 DE-101 | |
| 016 | 7 | |a 1063272408 |2 DE-101 | |
| 016 | 7 | |a 101535741 |2 DNLM | |
| 016 | 7 | |a 015673956 |2 Uk | |
| 019 | |a 711782115 |a 715190347 |a 723440261 |a 808669643 |a 816831078 |a 899164592 |a 960204595 |a 961512907 |a 962697696 |a 988486464 |a 992060515 |a 992914440 |a 1037942313 |a 1038602261 |a 1045472712 |a 1055389204 |a 1062911643 |a 1071984397 |a 1081249861 |a 1153450080 |a 1228548747 |a 1244447579 |a 1249239011 |a 1393054049 | ||
| 020 | |a 9780470929278 |q (electronic bk.) | ||
| 020 | |a 0470929278 |q (electronic bk.) | ||
| 020 | |a 9780470929261 |q (electronic bk.) | ||
| 020 | |a 047092926X |q (electronic bk.) | ||
| 020 | |z 9780470401965 | ||
| 020 | |z 0470401966 | ||
| 020 | |z 1283052326 | ||
| 020 | |z 9781283052320 | ||
| 024 | 8 | |a 9786613052322 | |
| 029 | 1 | |a AU@ |b 000047158553 | |
| 029 | 1 | |a AU@ |b 000051557867 | |
| 029 | 1 | |a AU@ |b 000060584931 | |
| 029 | 1 | |a CHBIS |b 006447515 | |
| 029 | 1 | |a CHBIS |b 009882739 | |
| 029 | 1 | |a CHNEW |b 000937679 | |
| 029 | 1 | |a CHVBK |b 174240589 | |
| 029 | 1 | |a CHVBK |b 480179867 | |
| 029 | 1 | |a DEBBG |b BV041048829 | |
| 029 | 1 | |a DEBBG |b BV043393066 | |
| 029 | 1 | |a DEBBG |b BV044151776 | |
| 029 | 1 | |a DEBSZ |b 485002167 | |
| 029 | 1 | |a GWDNB |b 1063272408 | |
| 029 | 1 | |a GWDNB |b 1066428301 | |
| 029 | 1 | |a NZ1 |b 14256174 | |
| 035 | |a (OCoLC)716211010 |z (OCoLC)711782115 |z (OCoLC)715190347 |z (OCoLC)723440261 |z (OCoLC)808669643 |z (OCoLC)816831078 |z (OCoLC)899164592 |z (OCoLC)960204595 |z (OCoLC)961512907 |z (OCoLC)962697696 |z (OCoLC)988486464 |z (OCoLC)992060515 |z (OCoLC)992914440 |z (OCoLC)1037942313 |z (OCoLC)1038602261 |z (OCoLC)1045472712 |z (OCoLC)1055389204 |z (OCoLC)1062911643 |z (OCoLC)1071984397 |z (OCoLC)1081249861 |z (OCoLC)1153450080 |z (OCoLC)1228548747 |z (OCoLC)1244447579 |z (OCoLC)1249239011 |z (OCoLC)1393054049 | ||
| 037 | |a 10.1002/9780470929278 |b Wiley InterScience |n http://www3.interscience.wiley.com | ||
| 050 | 4 | |a RM301.55 |b .M367 2011 | |
| 060 | 4 | |a QV 38 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615/.7 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Mass spectrometry in drug metabolism and disposition : |b basic principles and applications / |c edited by Mike S. Lee, Mingshe Zhu. |
| 260 | |a Hoboken, N.J. : |b Wiley, |c ©2011. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Wiley series on pharmaceutical science and biotechnology : practices, applications, and methods | |
| 505 | 0 | |6 880-01 |a Frontmatter -- Basic Concepts of Drug Metabolism and Disposition. Progression of Drug Metabolism / Ronald E White -- Common Biotransformation Reactions / Bo Wen, Sidney D Nelson -- Metabolic Activation of Organic Functional Groups Utilized in Medicinal Chemistry / Amit S Kalgutkar -- Drug-Metabolizing Enzymes, Transporters, and Drug-Drug Interactions / Steven W Louie, Magang Shou -- Experimental Models of Drug Metabolism and Disposition / Gang Luo, Chuang Lu, Xinxin Ding, Donglu Zhang -- Principles of Pharmacokinetics: Predicting Human Pharmacokinetics in Drug Discovery / Takehito Yamamoto, Hiroshi Suzuki, Akihiro Hisaka -- Drug Metabolism Research as Integral Part of Drug Discovery and Development Processes / W Griffith Humphreys -- Mass Spectrometry in Drug Metabolism: Principles and Common Practice. Theory and Instrumentation of Mass Spectrometry / Girard Hopfgartner -- Common Liquid Chromatography Mass Spectrometry (LCMS) Methodology for Metabolite Identification / Lin Xu, Lewis J Klunk, Chandra Prakash -- Mass Spectral Interpretation / Li-Kang Zhang, Birendra N Pramanik -- Techniques to Facilitate the Performance of Mass Spectrometry: Sample Preparation, Liquid Chromatography, and Non-Mass-Spectrometric Detection / Mark Hayward, Maria D Bacolod, Qing Ping Han, Manuel Cajina, Zack Zou -- Applications of New LCMS Techniques in Drug Metabolism and Disposition. Quantitative in Vitro ADME Assays Using LCMS as a Part of Early Drug Metabolism Screening / Walter Korfmacher -- High-Resolution Mass Spectrometry and Drug Metabolite Identification / Russell J Mortishire-Smith, Haiying Zhang, Kevin P Bateman -- Distribution Studies of Drugs and Metabolites in Tissue by Mass Spectrometric Imaging / Richard F Reich, Daniel P Magparangalan, Timothy J Garrett, Richard A Yost -- Use of Triple Quadrupole Linear Ion Trap Mass Spectrometry as a Single LCMS Platform in Drug Metabolism and Pharmacokinetics Studies / Wenying Jian, Ming Yao, Bo Wen, Elliott B Jones, Mingshe Zhu -- Quantitative Drug Metabolism with Accelerator Mass Spectrometry / John S Vogel, Peter Lohstroh, Brad Keck, Stephen R Dueker -- Standard-Free Estimation of Metabolite Levels Using Nanospray Mass Spectrometry: Current Statutes and Future Directions / Jing-Tao Wu -- Profiling and Characterization of Herbal Medicine and its Metabolites Using LCMS / Zeper Abliz, Ruiping Zhang, Ping Geng, Dongmei Dai, Jiuming He, Jian Liu -- Liquid Chromatography Mass Spectrometry Bioanalysis of Protein Therapeutics and Biomarkers in Biological Matrices / Fumin Li, Qin C Ji -- Mass Spectrometry in the Analysis of DNA, Protein, Peptide, and Lipid Biomarkers of Oxidative Stress / Stacy L Gelhaus, Ian A Blair -- LC²́⁶MS in Endogenous Metabolite Profiling and Small-Molecule Biomarker Discovery / Michael D Reily, Petia Shipkova, Serhiy Hnatyshyn -- Appendix -- Index. | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 8 | |a (Publisher-supplied data) Part I Basic Concepts of Drug Metabolism and Disposition -- The Progression of Drug Metabolism -- Common Biotransformation Reactions -- Metabolic Activation of Organic Functional Groups Utilized in Medicinal Chemistry -- Drug Metabolizing Enzymes, Transporters and Drug-Drug Interactions -- Experimental Models of Drug Metabolism and Disposition -- Principles of Pharmacokinetics: Predicting Human Pharmacokinetics -- Drug Metabolism Research as an Integral Part of the Drug Discovery and Development Processes -- Part II Mass Spectrometry in Drug Metabolism: Principles and Common Practice -- Theory and Instrumentation of Mass Spectrometry -- Common Liquid Chromatography-Mass Spectrometry (LC-MS) Methodology for Metabolite Identification -- Mass Spectral Interpretation -- Techniques to Facilitate the Performance of Mass Spectrometry: Sample Preparation, Liquid Chromatography and Non-Mass Spectrometric Detection -- Part III Applications of New LC/MS Techniques in Drug Metabolism and Disposition -- Quantitative In Vitro ADME Assays using LC-MS as a Part of Early Drug Metabolism Screening -- High Resolution Mass Spectrometry and Drug Metabolite Identification -- Distribution Studies of Drugs and Metabolites in Tissue by Mass Spectrometric Imaging -- Use of Triple Quadrupole-Linear Ion Trap Mass Spectrometry as a Single LC/MS Platform in Drug Metabolism and Pharmacokinetics Studies -- Quantitative Drug Metabolism with Accelerator Mass Spectrometry -- Standard-Free Estimation of Metabolite Levels Using Nanospray Mass Spectrometry: Current Statutes and Future Directions -- Profiling and Characterization of Herbal Medicine and their Metabolites using LC-MS -- Liquid Chromatography Mass Spectrometry Bioanalysis of Proteins in Biological Matrices -- Mass Spectrometry in the Analysis of DNA, Protein, Peptide, and Lipid Biomarkers of Oxidative Stress -- LC-MS in Endogenous Metabolite Profiling and Small Molecule Biomarker Discovery. | |
| 520 | |a "This book examines the background, industrial context, process, analytical methodology, and technology of metabolite identification. It emphasizes the applications of metabolite identification in drug research. While primarily a textbook, the book also functions as a comprehensive reference to those in the industry. The authors have worked closely together and combine complementary backgrounds to bring technical and cultural awareness to this very important endeavor while serving to address needs within academia and industry It also contains a variety of problem sets following specific sections in the text"--Provided by publisher. | ||
| 588 | 0 | |a Print version record. | |
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Drugs |x Metabolism |x Analysis. | |
| 650 | 0 | |a Metabolites |x Spectra. | |
| 650 | 0 | |a Mass spectrometry. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 0 | |a Pharmacokinetics. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Metabolism. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Life sciences. | |
| 650 | 0 | |a Medical personnel. | |
| 650 | 0 | |a Chemistry. | |
| 650 | 0 | |a Physical sciences. | |
| 650 | 0 | |a Drugs. | |
| 650 | 0 | |a Biopharmaceutics. | |
| 650 | 0 | |a Methodology. | |
| 650 | 1 | 2 | |a Pharmaceutical Preparations |x metabolism |
| 650 | 2 | 2 | |a Biopharmaceutics |x methods |
| 650 | 2 | 2 | |a Drug Design |
| 650 | 2 | 2 | |a Mass Spectrometry |x methods |
| 650 | 2 | 2 | |a Pharmacokinetics |
| 650 | 2 | |a Pharmacological Phenomena | |
| 650 | 2 | |a Drug Discovery | |
| 650 | 2 | |a Kinetics | |
| 650 | 2 | |a Chemistry Techniques, Analytical | |
| 650 | 2 | |a Pharmacology | |
| 650 | 2 | |a Investigative Techniques | |
| 650 | 2 | |a Metabolism | |
| 650 | 2 | |a Chemicals and Drugs | |
| 650 | 2 | |a Chemistry, Pharmaceutical | |
| 650 | 2 | |a Biological Science Disciplines | |
| 650 | 2 | |a Analytical, Diagnostic and Therapeutic Techniques and Equipment | |
| 650 | 2 | |a Phenomena and Processes | |
| 650 | 2 | |a Biochemical Phenomena | |
| 650 | 2 | |a Physiological Phenomena | |
| 650 | 2 | |a Health Occupations | |
| 650 | 2 | |a Chemical Phenomena | |
| 650 | 2 | |a Chemistry | |
| 650 | 2 | |a Natural Science Disciplines | |
| 650 | 2 | |a Disciplines and Occupations | |
| 650 | 2 | |a Pharmaceutical Preparations | |
| 650 | 2 | |a Biopharmaceutics | |
| 650 | 2 | |a Mass Spectrometry | |
| 650 | 2 | |a Methods | |
| 650 | 2 | |a Health Workforce. | |
| 650 | 2 | |a Health Personnel | |
| 650 | 4 | |a Health & Biological Sciences. | |
| 650 | 4 | |a Pharmacy, Therapeutics, & Pharmacology. | |
| 650 | 6 | |a Médicaments |x Métabolisme |x Analyse. | |
| 650 | 6 | |a Métabolites |x Spectre. | |
| 650 | 6 | |a Spectrométrie de masse. | |
| 650 | 6 | |a Médicaments |x Conception. | |
| 650 | 6 | |a Pharmacocinétique. | |
| 650 | 6 | |a Pharmacologie. | |
| 650 | 6 | |a Métabolisme. | |
| 650 | 6 | |a Chimie pharmaceutique. | |
| 650 | 6 | |a Sciences de la vie. | |
| 650 | 6 | |a Personnel médical. | |
| 650 | 6 | |a Chimie. | |
| 650 | 6 | |a Sciences physiques. | |
| 650 | 6 | |a Médicaments. | |
| 650 | 6 | |a Biopharmacie. | |
| 650 | 6 | |a Méthodologie. | |
| 650 | 7 | |a mass spectrometry. |2 aat | |
| 650 | 7 | |a pharmacology. |2 aat | |
| 650 | 7 | |a metabolism (biological concept) |2 aat | |
| 650 | 7 | |a biological sciences. |2 aat | |
| 650 | 7 | |a chemistry. |2 aat | |
| 650 | 7 | |a physical sciences. |2 aat | |
| 650 | 7 | |a methodology. |2 aat | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Physical sciences |2 fast | |
| 650 | 7 | |a Pharmacology |2 fast | |
| 650 | 7 | |a Pharmacokinetics |2 fast | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 650 | 7 | |a Methodology |2 fast | |
| 650 | 7 | |a Metabolism |2 fast | |
| 650 | 7 | |a Medical personnel |2 fast | |
| 650 | 7 | |a Life sciences |2 fast | |
| 650 | 7 | |a Drugs |x Design |2 fast | |
| 650 | 7 | |a Drugs |2 fast | |
| 650 | 7 | |a Chemistry |2 fast | |
| 650 | 7 | |a Biopharmaceutics |2 fast | |
| 650 | 7 | |a Mass spectrometry |2 fast | |
| 700 | 1 | |a Lee, Mike S., |d 1960- |1 https://id.oclc.org/worldcat/entity/E39PCjrQrr8rpF8t68MCqC6TjK | |
| 700 | 1 | |a Zhu, Mingshe. | |
| 758 | |i has work: |a Mass spectrometry in drug metabolism and disposition (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGXPMdWCFjk49QPH9pKbFq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Mass spectrometry in drug metabolism and disposition. |d Hoboken, N.J. : Wiley, ©2011 |z 9780470401965 |w (DLC) 2010028341 |w (OCoLC)648080364 |
| 830 | 0 | |a Wiley series on pharmaceutical science and biotechnology. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=675235 |z Texto completo |
| 880 | 0 | 0 | |6 505-01/(S |g Machine generated contents note: |g pt. I |t BASIC CONCEPTS OF DRUG METABOLISM AND DISPOSITION -- |g 1. |t Progression of Drug Metabolism / |r Ronald E. White -- |g 1.1. |t Introduction -- |g 1.2. |t Historical Phases of Drug Metabolism -- |g 1.2.1. |t "Chemistry" Phase (1950-1980) -- |g 1.2.2. |t "Biochemistry" Phase (1975---Present) -- |g 1.2.3. |t "Genetics" Phase (1990---Present) -- |g 1.2.4. |t "Biology" Phase (2010 and Beyond) -- |g 1.3. |t Next Step in the Progression of DM -- |g 1.3.1. |t New Regulatory Expectation -- |g 1.3.2. |t New Challenges for Technology -- |g 1.4. |t Perspective on the Magnitude of the Challenge -- |g 1.4.1. |t Ultimate Limits on Metabolite Quantitation -- |g 1.4.2. |t Practical Limits on Metabolite Quantitation -- |g 1.4.3. |t Natural Limit Due to Dose Size -- |g 1.5. |t Are There More Sensitive Alternatives to MS-- |g 1.6. |t Summary -- |t References -- |g 2. |t Common Biotransformation Reactions / |r Sidney D. Nelson -- |g 2.1. |t Introduction -- |g 2.2. |t Oxidative Reactions -- |g 2.2.1. |t Cytochrome P450 Oxidative Reactions -- |g 2.2.2. |t Oxidations by Flavin Monooxygenases -- |g 2.2.3. |t Oxidations by Monoamine Oxidases -- |g 2.2.4. |t Oxidations by Molybdenum Hydroxylases -- |g 2.2.5. |t Oxidations by Alcohol and Aldehyde Dehydrogenases -- |g 2.2.6. |t Oxidations by Peroxidases -- |g 2.3. |t Reductive Reactions -- |g 2.3.1. |t Reductions by Cytochrome P450s -- |g 2.3.2. |t Reductions by Molybdenum-Containing Enzymes -- |g 2.3.3. |t Reductions by Alcohol Dehydrogenases and Carbonyl Reductases -- |g 2.3.4. |t Reductions by Cytochrome P450 Reductase and Quinone Oxidoreductase -- |g 2.3.5. |t Reductions by Intestinal Microflora -- |g 2.4. |t Hydrolytic Reactions -- |g 2.4.1. |t Hydrolysis by Epoxide Hydrolases -- |g 2.4.2. |t Hydrolysis of Esters, Amides, and Related Structures -- |g 2.5. |t Glucuronidation Reactions -- |g 2.5.1. |t Glucuronidation of Hydroxy Groups -- |g 2.5.2. |t Glucuronidation of Amines and Amides -- |g 2.5.3. |t Glucuronidation of Thiols and Thiocarbonyl Compounds -- |g 2.5.4. |t Glucuronidation of Relatively Acidic Carbon Atoms -- |g 2.6. |t Sulfation Reactions -- |g 2.6.1. |t Sulfation of Alcohols -- |g 2.6.2. |t Sulfation of Hydroxylamines and Hydroxyamides -- |g 2.6.3. |t Sulfation of Amines and Amides -- |g 2.7. |t Acylation Reactions -- |g 2.7.1. |t Acetylation of Primary Amines and Hydrazines -- |g 2.7.2. |t Amino Acid Conjugation of Carboxylic Acids -- |g 2.7.3. |t Chemical Acylations -- |g 2.8. |t Methylation Reactions -- |g 2.8.1. |t Methylation of Catechols -- |g 2.8.2. |t Methylation of Thiols -- |g 2.8.3. |t Methylation of Amines -- |g 2.9. |t Glutathione Conjugation Reactions -- |g 2.9.1. |t GSH Conjugation of Epoxides -- |g 2.9.2. |t GSH Conjugation of Conjugated Enone/Enal and Similar Systems -- |g 2.9.3. |t GSH Conjugations at Saturated and Unsaturated Carbon Atoms -- |g 2.9.4. |t GSH Conjugation at Heteroatoms -- |g 2.10. |t Conclusions -- |t References -- |g 3. |t Metabolic Activation of Organic Functional Groups Utilized in Medicinal Chemistry / |r Amit S. Kalgutkar -- |g 3.1. |t Introduction -- |g 3.2. |t Bioactivation of Drugs -- |g 3.3. |t Experimental Strategies to Detect Reactive Metabolites -- |g 3.4. |t Functional Group Metabolism to Reactive Intermediates -- |g 3.4.1. |t Two-Electron Oxidations on Electron-Rich Aromatic Ring Systems -- |g 3.4.2. |t N-Hydroxylation of Anilines -- |g 3.4.3. |t Hydrazines -- |g 3.4.4. |t Bioactivation of Reduced Thiols -- |g 3.4.5. |t Epoxidation of sp2 and sp Centers -- |g 3.4.6. |t Thiazolidinedione Ring Bioactivation -- |g 3.4.7. |t α, β-Unsaturated Carbonyl Compounds -- |g 3.4.8. |t Haloalkanes -- |g 3.4.9. |t Carboxylic Acids -- |g 3.5. |t Structural Alerts and Drug Design -- |g 3.6. |t Reactive Metabolite Trapping and Covalent Binding Studies as Predictors of Idiosyncratic Drug Toxicity -- |g 3.7. |t Dose as an Important Mitigating Factor for IADRs -- |g 3.8. |t Concluding Remarks -- |t References -- |g 4. |t Drug-Metabolizing Enzymes, Transporters, and Drug---Drug Interactions / |r Magang Shou -- |g 4.1. |t Introduction -- |g 4.2. |t Drug-Metabolizing Enzymes -- |g 4.2.1. |t CYPs -- |g 4.2.2. |t UDP---Glucuronosyl transferases -- |g 4.2.3. |t Sulfotransferases -- |g 4.2.4. |t Glutathione-S-Transferases -- |g 4.2.5. |t Regulation of Human CYPs -- |g 4.3. |t Metabolism-Based DDIs -- |g 4.3.1. |t Reaction Phenotyping -- |g 4.3.2. |t Reversible CYP Inhibition -- |g 4.3.3. |t Time-Dependent Inhibition -- |g 4.3.4. |t Prediction of Clinical DDIs from CYP Induction -- |g 4.3.5. |t Factors Affecting DDI Prediction -- |g 4.4. |t CYP Conclusion -- |g 4.5. |t Drug Transporters -- |g 4.5.1. |t Key ADME Transporters -- |g 4.6. |t Tools of the Transporter Trade -- |g 4.6.1. |t Absorption and Permeability -- |g 4.6.2. |t Caco-2 Permeability -- |g 4.6.3. |t PAMPA -- |g 4.6.4. |t Immobilized Artificial Membrane -- |g 4.7. |t Uptake and Efflux Transporter Tools -- |g 4.7.1. |t Transfected Cell Lines -- |g 4.7.2. |t Uptake Assays -- |g 4.7.3. |t Transwell Efflux Assays -- |g 4.7.4. |t Membrane Vesicles -- |g 4.7.5. |t Hepatocyte Sandwich Cultures -- |g 4.7.6. |t Transgenic Mice -- |g 4.8. |t Sample Analysis -- |g 4.9. |t Automation -- |g 4.9.1. |t Cell Maintenance Systems -- |g 4.9.2. |t Robotic Liquid-Handling Systems -- |g 4.10. |t In Vitro DDI Assays -- |g 4.11. |t In Vitro---In Vivo Correlations -- |g 4.12. |t Kinetic Models -- |g 4.13. |t Transporter Conclusion -- |t Acknowledgment -- |t References -- |g 5. |t Experimental Models of Drug Metabolism and Disposition / |r Donglu Zhang -- |g 5.1. |t Introduction -- |g 5.2. |t ADME Study Strategy in Drug Discovery -- |g 5.2.1. |t Step-by-Step Strategy -- |g 5.2.2. |t Issue-Driven Strategy -- |g 5.2.3. |t PK---PD and PK---TK Considerations -- |g 5.3. |t ADME Experimental Models -- |g 5.3.1. |t In Vitro Models -- |g 5.3.2. |t In Situ and Ex Vivo Models -- |g 5.3.3. |t In Vivo Models -- |g 5.3.4. |t Engineered Mouse Models -- |g 5.3.5. |t In Silico Modeling -- |g 5.4. |t Data Interpretation -- |g 5.4.1. |t Species Difference -- |g 5.4.2. |t In vitro---In Vivo Discrepancy -- |g 5.4.3. |t Enzyme---Transporter Interplay -- |g 5.4.4. |t Interindividual Differences -- |g 5.4.5. |t Drug---Drug Interaction -- |g 5.4.6. |t Multiple Other Factors Affecting Metabolic Pathways -- |g 5.5. |t Summary -- |t Acknowledgments -- |t References -- |g 6. |t Principles of Pharmacokinetics: Predicting Human Pharmacokinetics in Drug Discovery / |r Hiroshi Suzuki -- |g 6.1. |t Introduction -- |g 6.1.1. |t General Introduction -- |g 6.1.2. |t Relationship between Drug Efficacy and Concentration -- |g 6.1.3. |t Prediction of Pharmacokinetics by Extrapolation from Animal Data -- |g 6.2. |t Physiological Pharmacokinetics -- |g 6.2.1. |t Why Is a Physiological Pharmacokinetic Model Necessary-- |g 6.2.2. |t Clearance -- |g 6.2.3. |t Volume of Distribution -- |g 6.2.4. |t Relationship between Intrinsic Clearance and Organ Clearance -- |g 6.2.5. |t Estimation of Permeability-Limited Clearance -- |g 6.3. |t Prediction of Absorption -- |g 6.3.1. |t Determinants of Bioavailability -- |g 6.3.2. |t Absorption Ratio -- |g 6.3.3. |t Dosing Vehicle and Feeding State -- |g 6.3.4. |t Evaluation Methods for Absorption -- |g 6.3.5. |t Intestinal Availability -- |g 6.4. |t Distribution -- |g 6.4.1. |t Plasma Protein Binding -- |g 6.4.2. |t Relationship between Drug Efficacy and Protein Binding -- |g 6.5. |t Metabolism and excretion -- |g 6.5.1. |t Estimation of Clearance -- |g 6.5.2. |t Estimation of Hepatic Intrinsic Clearance -- |g 6.5.3. |t Determination of Hepatic Intrinsic Metabolic Clearance from in vitro Experimental Data -- |g 6.5.4. |t Estimation of Renal Clearance -- |g 6.6. |t Drug---Drug interactions -- |g 6.6.1. |t Importance of Determining the Contribution Ratio for Prediction of Drug---Drug Interactions -- |g 6.6.2. |t Methods for Determination of the Contribution Ratio -- |g 6.7. |t Practical issues That Need to Be Considered -- |g 6.7.1. |t Evaluation of PK During the Exploratory Stage -- |g 6.7.2. |t Evaluation of PK During the Development Stage -- |t Abbrevations and Notations -- |t References -- |g 7. |t Drug Metabolism Research as Integral Part of Drug Discovery and Development Processes / |r W. |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH13355905 | ||
| 938 | |a 123Library |b 123L |n 16187 | ||
| 938 | |a Coutts Information Services |b COUT |n 17671258 |c 96.95 GBP | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL675235 | ||
| 938 | |a ebrary |b EBRY |n ebr10456208 | ||
| 938 | |a EBSCOhost |b EBSC |n 363481 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 305232 | ||
| 938 | |a YBP Library Services |b YANK |n 3350590 | ||
| 938 | |a YBP Library Services |b YANK |n 3537300 | ||
| 938 | |a YBP Library Services |b YANK |n 12667968 | ||
| 938 | |a Internet Archive |b INAR |n isbn_9780470401965 | ||
| 994 | |a 92 |b IZTAP | ||